Showing 4841-4850 of 8859 results for "".
- Etrasimod Performs Well in Phase Phase 2b Trial of Adult Atopic Dermatitishttps://practicaldermatology.com/news/etrasimod-performs-well-in-phase-phase-2b-trial-of-adult-atopic-dermatitis/2460761/Arena Pharmaceuticals, Inc.’s Etrasimod demonstrated statistical significance in both clinician and patient reported outcomes in atopic dermatitis, according to research presented at the American Academy of Dermatology VMX Experience. Etrasimod is an investigational, highly select
- Data Show Long-term Safety, Clinical Benefit of Dupilumab in Pediatric ADhttps://practicaldermatology.com/news/data-show-long-term-safety-clinical-benefit-of-dupilumab-in-pediatric-ad/2460757/Dupilumab (Dupixent, Sanofi/Regeneron) is safe and effective for the long-term management of atopic dermatitis in patients as young as six, data from a collection of posters presented at the AAD 2021 VMX show. One study
- GEMME Webinar Series to Assess Impact of Essential Mask Wearing on Skinhttps://practicaldermatology.com/news/gemme-webinar-series-to-assess-impact-of-essential-mask-wearing-on-skin/2460754/Assessing the impact of essential mask wearing, the first of a series of four webinars from GEMME (Galderma Excellence Multichannel Medical Education) launches next month. “Under the mask: the consequences of essential mask wearing,” will stream Saturday, May 8, with Drs. Lu
- Kintor Doses First Group of Acne Patients in Phase I/II Clinical Trial of Pyrilutamidehttps://practicaldermatology.com/news/kintor-doses-first-group-of-acne-patients-in-phase-iii-clinical-trial-of-pyrilutamide/2460752/Kintor Pharmaceutical Limited successfully dosed the first group of patients in the clinical trial of Pyrilutamide as a treatment for the acne vulgaris. The Phase I/II clinical trial in China is a randomized, double-blind, placebo-controlled clinical study to evalu
- First Launch from FlawlessCanvas Now Availablehttps://practicaldermatology.com/news/first-launch-from-flawlesscanvas-now-available/2460750/Quantum Lift Reset Serum™ is now available from FlawlessCanvas, Inc., direct to its Facebook and Instagram followers. “The design of FlawlessCanvas Quantum Lift Reset Serum™ was based on
- ASDSA Alerts Nation’s Governors to New Trend in Anti-transgender Legislationhttps://practicaldermatology.com/news/asdsa-alerts-nations-governors-to-new-trend-in-anti-transgender-legislation/2460749/The American Society for Dermatologic Surgery Association (ASDSA) sent a letter to all 50 state governors along with legislative leaders, alerting them to the increase in anti-transgender legislation that is proliferating in state legislatures across the country. After Arkansas be
- Yale Cancer Center Study Highlights Novel Immunotherapy Approach to Fight Melanomahttps://practicaldermatology.com/news/yale-cancer-center-study-shows-novel-immunotherapy-approach-to-fight-melanoma/2460748/A tumor-targeting and cell-penetrating antibody can stimulate an immune response to help treat melanoma, Yale researchers reported at the American Association of Cancer Research (AACR) virtual annual meeting. “Most approaches rely on direct injection into tumors of ribonucleic aci
- Arcutis Initiates Phase 3 Clinical Trial of Topical Roflumilast Cream for Pediatric ADhttps://practicaldermatology.com/news/arcutis-initiates-phase-3-clinical-trial-of-topical-roflumilast-cream-for-pediatric-ad/2460743/Arcutis Biotherapeutics, Inc. initiated a pivotal Phase 3 clinical trial evaluating topical roflumilast cream (ARQ-151) as a potential treatment for mild to moderate atopic dermatitis (AD) in patients between the ages of 2 and 5 years old. Roflumilast cream is a once daily topical formulation of
- Galderma's Nemolizumab Performs Well in Phase 2b for ADhttps://practicaldermatology.com/news/galdermas-nemolizumab-performs-well-in-phase-2b-for-ad/2460739/Investigational nemolizumab led to rapid and sustained improvements in itch, sleep, and skin lesions in adult patients with uncontrolled moderate-to-severe AD in phase 2 studies published in Journal of the European Academy of Dermatology and Venereology (JEADV) and reported by
- Dermatological Advocates Present Dr. Adam Friedman with Advocacy Leadership Awardhttps://practicaldermatology.com/news/dermatological-advocates-present-dr-adam-friedman-with-advocacy-leadership-award/2460738/The Derma Care Access Network (DCAN), a national non-profit coalition advocating for patient access to optimal dermatological care, is recognizing Adam Friedman, MD with its inaugural Advocacy Leadership Award for his work as a passionate advocate and